U.S. Physical Therapy (USPH)
(Delayed Data from NYSE)
$106.39 USD
+1.36 (1.29%)
Updated May 10, 2024 04:00 PM ET
After-Market: $106.58 +0.19 (0.18%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth B Momentum C VGM
U.S. Physical Therapy (USPH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$120.63 | $122.50 | $117.00 | 14.85% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for U.S. Physical Therapy comes to $120.63. The forecasts range from a low of $117.00 to a high of $122.50. The average price target represents an increase of 14.85% from the last closing price of $105.03.
Analyst Price Targets (4 )
Broker Rating
U.S. Physical Therapy currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/1/2024 | Barrington Research | Michael J Petusky | Strong Buy | Strong Buy |
2/5/2024 | William Blair | Jared Haase | Not Available | Hold |
9/19/2023 | CJS Securities | Lawrence S Solow | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $120.63 |
LT Growth Rate | 9.10% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 68 of 252 |
Current Quarter EPS Est: | 0.83 |